References
- Baber N., Halliday L. D. C., Van Den Heuvel W. J. A., Walker R. W., Sibeon R., Keenan J. P., Littler T., Orme M. Indomethacin in rheumatoid arthritis. Clinical effects, pharmacokinetics and platelet studies in responders and non-responders. Ann. Rheum. Dis. 1979; 38: 128–1371. Baber N., Halliday L. D. C., Van Den Heuvel W. J. A., Walker R. W., Sibeon R., Keenan J. P., Littler T., Orme M. Indomethacin in rheumatoid arthritis. Clinical effects, pharmacokinetics and platelet studies in responders and non-responders. Ann. Rheum. Dis. 1979; 38: 128–137
- Hart C., Rhymer A., Mila S. Indocin SR (Indomethacin, MSD), in the treatment of moderate to severe rheumatoid arthritis. Semin. Arthr. Rheum. 1982; 2: 147–1512. Hart C., Rhymer A., Mila S. Indocin SR (Indomethacin, MSD), in the treatment of moderate to severe rheumatoid arthritis. Semin. Arthr. Rheum. 1982; 2: 147–151
- Helleberg L. Clinical pharmacokinetics of indomethacin. Clin. Pharmacokin. 1981; 6: 245–2583. Helleberg L. Clinical pharmacokinetics of indomethacin. Clin. Pharmacokin. 1981; 6: 245–258
- Huskisson E.C. Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clin. Rheum. Dis. 1979; 5: 697–7064. Huskisson E.C. Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clin. Rheum. Dis. 1979; 5: 697–706
- Kaarela K., Lehtinen K., Mäkisara P., Holttinen K., Lamminsivu U., Gordin A. Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis. Eur. J. Clin. Pharmacol. 1982; 23: 345–3515. Kaarela K., Lehtinen K., Mäkisara P., Holttinen K., Lamminsivu U., Gordin A. Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis. Eur. J. Clin. Pharmacol. 1982; 23: 345–351
- Lehtinen K., Kaarela K., Makisara P., Holttinen K., Gordin A. Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis. Br. J. Rheum. 1984; 23: 52–566. Lehtinen K., Kaarela K., Makisara P., Holttinen K., Gordin A. Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis. Br. J. Rheum. 1984; 23: 52–56
- Metzner J., Bekemeier H., Kala H., Hanke P., Schmollack W. Klinisch-pharmakologische Untersuchung einer oralen Depot-artzneiform auf Silikonharzbasis mit indomethacin als Wirkstoff. Z. Gesamte Inn. Med. 1980; 35: 366–3707. Metzner J., Bekemeier H., Kala H., Hanke P., Schmollack W. Klinisch-pharmakologische Untersuchung einer oralen Depot-artzneiform auf Silikonharzbasis mit indomethacin als Wirkstoff. Z. Gesamte Inn. Med. 1980; 35: 366–370
- Rhymer A. R., Gengos D.C. Indomethacin. Clin. Rheum. Dis. 1979; 5: 541–5528. Rhymer A. R., Gengos D.C. Indomethacin. Clin. Rheum. Dis. 1979; 5: 541–552
- Rhymer A., Hart C., Daurio C. A double-blind trial comparing indomethacin sustained release capsules (Indocid-R) with indomethacin capsules in patients with rheumatoid arthritis. Rheumatol. Rehabil 1982; 21: 101–1069. Rhymer A., Hart C., Daurio C. A double-blind trial comparing indomethacin sustained release capsules (Indocid-R) with indomethacin capsules in patients with rheumatoid arthritis. Rheumatol. Rehabil 1982; 21: 101–106
- Schoog W., Laufen H., Dessain P. A comparison of the pharmacokinetics of piroxicam with those of plain and slow release indomethacin. A crossover study. Eur. J. Rheumatol. Inflammation 1981; 4: 298–30210. Schoog W., Laufen H., Dessain P. A comparison of the pharmacokinetics of piroxicam with those of plain and slow release indomethacin. A crossover study. Eur. J. Rheumatol. Inflammation 1981; 4: 298–302
- Waller E. S. Evaluation of new indomethacin dosage forms. Pharmacotherapy. 1983; 3: 324–33311. Waller E. S. Evaluation of new indomethacin dosage forms. Pharmacotherapy. 1983; 3: 324–333
- Vignon E., Chapuy M. Biodisponibilité de l'indométhacine, étude d'une présentation effect retard. Rev. Rhum. Mai. Osteoartic 1979; 46: 505–50812. Vignon E., Chapuy M. Biodisponibilité de l'indométhacine, étude d'une présentation effect retard. Rev. Rhum. Mai. Osteoartic 1979; 46: 505–508